Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Seroepidemiology as basis for design of a human papillomavirus vaccination program.

Ryding, Janka LU ; French, K M ; Naucler, Pontus LU ; Barnabas, R V ; Garnett, G P and Dillner, Joakim LU (2008) In Vaccine Aug 8. p.5263-5268
Abstract
We have performed a serological survey of HPV type 16-antibody prevalence by age and sex in Sweden and used it as a basis for modelling the optimal vaccination strategies in this population. Samples of 3317 subjects were tested for HPV16-specific antibodies. The observed age-specific seroprevalences along with sexual behaviour data were used to infer parameter values for a mathematical model representing Sweden and the preventive effect of possible strategies estimated. By the year 2055, vaccination of females starting at age 12 in 2008 was most efficient, estimated to prevent 5.8 million cumulative HPV16 infections. Catch-up programs had a strong additional preventive effect. Vaccination also targeting males increased protective effect by... (More)
We have performed a serological survey of HPV type 16-antibody prevalence by age and sex in Sweden and used it as a basis for modelling the optimal vaccination strategies in this population. Samples of 3317 subjects were tested for HPV16-specific antibodies. The observed age-specific seroprevalences along with sexual behaviour data were used to infer parameter values for a mathematical model representing Sweden and the preventive effect of possible strategies estimated. By the year 2055, vaccination of females starting at age 12 in 2008 was most efficient, estimated to prevent 5.8 million cumulative HPV16 infections. Catch-up programs had a strong additional preventive effect. Vaccination also targeting males increased protective effect by about 4%, but had lower preventive effect per vaccination given. Addition of an HPV serosurvey to existing models and data has enabled us to estimate effect of different vaccination strategies, optimized to the HPV epidemiology in our population. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Vaccine
volume
Aug 8
pages
5263 - 5268
publisher
Elsevier
external identifiers
  • wos:000260148900007
  • pmid:18692109
  • scopus:50849092853
  • pmid:18692109
ISSN
1873-2518
DOI
10.1016/j.vaccine.2008.07.041
language
English
LU publication?
yes
id
0abf2563-142b-494a-8159-6aba95409018 (old id 1223352)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18692109?dopt=Abstract
date added to LUP
2016-04-04 07:10:15
date last changed
2022-01-29 01:49:36
@article{0abf2563-142b-494a-8159-6aba95409018,
  abstract     = {{We have performed a serological survey of HPV type 16-antibody prevalence by age and sex in Sweden and used it as a basis for modelling the optimal vaccination strategies in this population. Samples of 3317 subjects were tested for HPV16-specific antibodies. The observed age-specific seroprevalences along with sexual behaviour data were used to infer parameter values for a mathematical model representing Sweden and the preventive effect of possible strategies estimated. By the year 2055, vaccination of females starting at age 12 in 2008 was most efficient, estimated to prevent 5.8 million cumulative HPV16 infections. Catch-up programs had a strong additional preventive effect. Vaccination also targeting males increased protective effect by about 4%, but had lower preventive effect per vaccination given. Addition of an HPV serosurvey to existing models and data has enabled us to estimate effect of different vaccination strategies, optimized to the HPV epidemiology in our population.}},
  author       = {{Ryding, Janka and French, K M and Naucler, Pontus and Barnabas, R V and Garnett, G P and Dillner, Joakim}},
  issn         = {{1873-2518}},
  language     = {{eng}},
  pages        = {{5263--5268}},
  publisher    = {{Elsevier}},
  series       = {{Vaccine}},
  title        = {{Seroepidemiology as basis for design of a human papillomavirus vaccination program.}},
  url          = {{http://dx.doi.org/10.1016/j.vaccine.2008.07.041}},
  doi          = {{10.1016/j.vaccine.2008.07.041}},
  volume       = {{Aug 8}},
  year         = {{2008}},
}